First-in-human Study of AZD5153, A Small-molecule Inhibitor of Bromodomain Protein 4, in Patients with Relapsed/Refractory Malignant Solid Tumors and Lymphoma

AZD5153, a reversible, bivalent inhibitor of the bromodomain and extraterminal family protein BRD4, has preclinical activity in multiple tumors. This first-in-human, phase I study investigated AZD5153 alone or with olaparib in patients with relapsed/refractory solid tumors or lymphoma. Adults with r...

Descripción completa

Detalles Bibliográficos
Autores principales: Hamilton, Erika P., Wang, Judy S., Oza, Amit M., Patel, Manish R., Ulahannan, Susanna V., Bauer, Todd, Karlix, Janet L., Zeron-Medina, Jorge, Fabbri, Giulia, Marco-Casanova, Paola, Moorthy, Ganesh, Hattersley, Maureen M., Littlewood, Gillian M., Mitchell, Patrick, Saeh, Jamal, Pouliot, Gayle P., Moore, Kathleen N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2023
Materias:
Small Molecule Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544002/
https://www.ncbi.nlm.nih.gov/pubmed/37486983
http://dx.doi.org/10.1158/1535-7163.MCT-23-0065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10544002/
https://www.ncbi.nlm.nih.gov/pubmed/37486983
http://dx.doi.org/10.1158/1535-7163.MCT-23-0065

Ejemplares similares